Citation： 張毅. Molecular classification and treatment in breast cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2014, 21(5): 525-531. doi: 10.7507/1007-9424.20140129 Copy
Copyright ? the editorial department of CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY of West China Medical Publisher. All rights reserved
| 1. | Perou CM, S?rlie T, Eisen MB, et al.Molecular portraits of human breast tumours[J].Nature, 2000, 406(6797):747-752. |
| 2. | Goldhirsch A, Wood WC, Coates AS, et al.Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J].Ann Oncol, 2011, 22(8):1736-1747. |
| 3. | 連臻強, 何潔華, 王曦, 等.乳腺癌不同分子亞型的臨床特點和生存分析[J/CD].中華乳腺病雜志:電子版, 2009, 3(2):139-146. |
| 4. | Carey LA, Perou CM, Livasy CA, et al.Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study[J].JAMA, 2006, 295(21):2492-2502. |
| 5. | Chlebowski RT, Chen Z, Anderson GL, et al.Ethnicity and breast cancer:factors influencing differences in incidence and outcome[J].J Natl Cancer Inst, 2005, 97(6):439-448. |
| 6. | NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines):Breast Cancer[EB/OL].Version 2.2013.www.nccn.com.http://infoonco.es/wp-content/uploads/2011/10/breast_cancer_2.2013.pdf. |
| 7. | Cuzick J, Sestak I, Baum M, et al.Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer:10-year analysis of the ATAC trial[J].Lancet Oncol, 2010, 11(12):1135-1141. |
| 8. | Huober J, Cole BF, Rabaglio M, et al.Symptoms of endocrine treatment and outcome in the BIG 1-98 study[J].Breast Cancer Res Treat, 2014, 143(1):159-169. |
| 9. | van de Velde CJ, Rea D, Seynaeve C, et al.Adjuvant tamoxifen and exemestane in early breast cancer (TEAM):a randomised phase 3 trial[J].Lancet, 2011, 377(9762):321-331. |
| 10. | Davies C, Pan H, Godwin J, et al.Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer:ATLAS, a randomised trial[J].Lancet, 2013, 381(9869):805-816. |
| 11. | Goss PE, Ingle JN, Martino S, et al.Impact of premenopausal status at breast cancer diagnosis in women entered on the placebocontrolled NCIC CTG MA17 trial of extended adjuvant letrozole[J].Ann Oncol, 2013, 24(2):355-361. |
| 12. | Berry DA, Cirrincione C, Henderson IC, et al.Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer[J].JAMA, 2006, 295(14):1658-1667. |
| 13. | International Breast Cancer Study Group (IBCSG).Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer:a randomized trial[J].J Natl Cancer Inst, 2002, 94(14):1054-1065. |
| 14. | Mehta RS, Barlow WE, Albain KS, et al.Combination anastrozole and fulvestrant in metastatic breast cancer[J].N Engl J Med, 2012, 367(5):435-444. |
| 15. | Bergh J, J?nsson PE, Lidbrink EK, et al.FACT:an open-label randomized phaseⅢstudy of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer[J].J Clin Oncol, 2012, 30(16):1919-1925. |
| 16. | Hugh J, Hanson J, Cheang MC, et al.Breast cancer subtypes and response to docetaxel in node-positive breast cancer:use of an immunohistochemical definition in the BCIRG 001 trial[J].J Clin Oncol, 2009, 27(8):1168-1176. |
| 17. | Roché H, Fumoleau P, Spielmann M, et al.Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients:the FNCLCC PACS 01 Trial[J].J Clin Oncol, 2006, 24(36):5664-5671. |
| 18. | Benz CC, Scott GK, Sarup JC, et al.Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu[J].Breast Cancer Res Treat, 1992, 24(2):85-95. |
| 19. | Ellis MJ, Coop A, Singh B, et al.Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer:evidence from a phaseⅢrandomized trial[J].J Clin Oncol, 2001, 19(18):3808-3816. |
| 20. | Kong X, Moran MS, Zhang N, et al.Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients[J].Eur J Cancer, 2011, 47(14):2084-2090. |
| 21. | 周波, 謝菲, 楊德啟.乳腺癌分子亞型預測新輔助化療療效的研究[J].中國腫瘤臨床, 2009, 36(4):199-202, 206. |
| 22. | Gianni L, Eiermann W, Semiglazov V, et al.Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial):a randomised controlled superiority trial with a parallel HER2-negative cohort[J].Lancet, 2010, 375(9712):377-384. |
| 23. | S?rlie T, Perou CM, Tibshirani R, et al.Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications[J].Proc Natl Acad Sci USA, 2001, 98(19):10869-10874. |
| 24. | Hayes DF, Thor AD, Dressler LG, et al.HER2 and response to paclitaxel in node-positive breast cancer[J].N Engl J Med, 2007, 357(15):1496-1506. |
| 25. | Press MF, Sauter G, Buyse M, et al.Alteration of topoisomeraseⅡ-alpha gene in human breast cancer:association with responsiveness to anthracycline-based chemotherapy[J].J Clin Oncol, 2011, 29(7):859-867. |
| 26. | Tan-Chiu E, Yothers G, Romond E, et al.Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer:NSABP B-31[J].J Clin Oncol, 2005, 23(31):7811-7819. |
| 27. | Slamon D, Eiermann W, Robert N, et al.Adjuvant trastuzumab in HER2-positive breast cancer[J].N Engl J Med, 2011, 365(14):1273-1283. |
| 28. | Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al.Herceptin Adjuvant (HERA) Trial Study Team.Trastuzumab after adju vant chemotherapy in HER2-positive breast cancer[J].N Engl J Med, 2005, 353(16):1659-1672. |
| 29. | Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al.2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA):an open-label, randomised controlled trial[J].Lancet, 2013, 382(9897):1021-1028. |
| 30. | Pivot X, Romieu G, Debled M, et al.6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE):a randomised phase 3 trial[J].Lancet Oncol, 2013, 14(8):741-748. |
| 31. | Slamon D, Eiermann W, Robert N, et al.PhaseⅢrandomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in her2neu positive early breast cancer patients:BCIRG 006 Study[J].Cancer Res, 2009, 69(24):Supplement 3. |
| 32. | Baselga J, Bradbury I, Eidtmann H, et al.Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO):a randomised, open-label, multicentre, phase 3 trial[J].Lancet, 2012, 379(9816):633-640. |
| 33. | Slamon DJ, Leyland-Jones B, Shak S, et al.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J].N Engl J Med, 2001, 344(11):783-792. |
| 34. | Marty M, Cognetti F, Maraninchi D, et al.Randomized phaseⅡtrial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:the M77001 study group[J].J Clin Oncol, 2005, 23(19):4265-4274. |
| 35. | Valero V, Forbes J, Pegram MD, et al.Multicenter phaseⅢrandomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study):two highly active therapeutic regimens[J].J Clin Oncol, 2011, 29(2):149-156. |
| 36. | Extra JM, Antoine EC, Vincent-Salomon A, et al.Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients:the observational Hermine study[J].Oncologist, 2010, 15(8):799-809. |
| 37. | Bachelot T, Romieu G, Campone M, et al.Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE):a singlegroup phase 2 study[J].Lancet Oncol, 2013, 14(1):64-71. |
| 38. | Dent R, Trudeau M, Pritchard KI, et al.Triple-negative breast cancer:clinical features and patterns of recurrence[J].Clin Cancer Res, 2007, 13(15 Pt 1):4429-4434. |
| 39. | De Laurentiis M, Cianniello D, Caputo R, et al.Treatment of triple negative breast cancer (TNBC):current options and future perspectives[J].Cancer Treat Rev, 2010, 36 Suppl 3:S80-S86. |
| 40. | de Ruijter TC, Veeck J, Tjan-Heijnen VC, et al.Characteristics of triple-negative breast cancer[J].J Cancer Res Clin Oncol, 2011, 137(2):183-192. |
| 41. | Nielsen TO, Hsu FD, Jensen K, et al.Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma[J].Clin Cancer Res, 2004, 10(16):5367-5374. |
| 42. | Abd El-Rehim DM, Ball G, Pinder SE, et al.High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses[J].Int J Cancer, 2005, 116(3):340-350. |
| 43. | Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al.Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer:final analysis of the randomized FinXX trial[J].J Clin Oncol, 2012, 30(1):11-18. |
| 44. | Wu J, Li S, Jia W, et al.Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triplenegative breast cancer[J].J Cancer Res Clin Oncol, 2011, 137(10):1505-1510. |
| 45. | Silver DP, Richardson AL, Eklund AC, et al.Efficacy of neoadjuvant cisplatin in triple-negative breast cancer[J].J Clin Oncol, 2010, 28(7):1145-1153. |
| 46. | Von Minckwitz G.A randomized phaseⅡtrial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto-GBG 66)[J].J Clin Oncol, 2013, suppl, abstr 1004. |
| 47. | Sikov WM, Berry DA, Perou CM, et al.Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC):CALGB 40603(Alliance)[C].The 2013 San Antonio Breast Cancer Symposium, December 10-14, 2013, Abstract S5-0. |
| 48. | Baselga J, Gomez P, Awada A, et al.The addition of cetuximab to cisplatin increases overall response rate (ORR) and progressionfree survival (PFS) in metastatic triple-negative breast cancer (TNBC):results of a randomized phaseⅡstudy (BALI-1)[J].Ann Oncol, 2010, 21(Suppl 8):2740. |
| 49. | Cameron D, Brown J, Dent R, et al.Adjuvant bevacizumabcontaining therapy in triple-negative breast cancer (BEATRICE):primary results of a randomised, phase 3 trial[J].Lancet Oncol, 2013, 14(10):933-942. |
| 50. | O'Shaughnessy J, Osborne C, Pippen JE, et al.Iniparib plus chemotherapy in metastatic triple-negative breast cancer[J].N Engl J Med, 2011, 364(3):205-214. |
| 51. | Gelmon KA, Tischkowitz M, Mackay H, et al.Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer:a phase 2, multicentre, open-label, non-randomised study[J].Lancet Oncol, 2011, 12(9):852-861. |
| 52. | Finetti P, Cervera N, Charafe-Jauffret E, et al.Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis[J].Cancer Res, 2008, 68(3):767-776. |
| 53. | Lavasani MA, Moinfar F.Molecular classification of breast carcinomas with particular emphasis on "basal-like" carcinoma:a critical review[J].Biophotonics, 2012, 5(4):345-366. |
- 1. Perou CM, S?rlie T, Eisen MB, et al.Molecular portraits of human breast tumours[J].Nature, 2000, 406(6797):747-752.
- 2. Goldhirsch A, Wood WC, Coates AS, et al.Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J].Ann Oncol, 2011, 22(8):1736-1747.
- 3. 連臻強, 何潔華, 王曦, 等.乳腺癌不同分子亞型的臨床特點和生存分析[J/CD].中華乳腺病雜志:電子版, 2009, 3(2):139-146.
- 4. Carey LA, Perou CM, Livasy CA, et al.Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study[J].JAMA, 2006, 295(21):2492-2502.
- 5. Chlebowski RT, Chen Z, Anderson GL, et al.Ethnicity and breast cancer:factors influencing differences in incidence and outcome[J].J Natl Cancer Inst, 2005, 97(6):439-448.
- 6. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines):Breast Cancer[EB/OL].Version 2.2013.www.nccn.com.http://infoonco.es/wp-content/uploads/2011/10/breast_cancer_2.2013.pdf.
- 7. Cuzick J, Sestak I, Baum M, et al.Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer:10-year analysis of the ATAC trial[J].Lancet Oncol, 2010, 11(12):1135-1141.
- 8. Huober J, Cole BF, Rabaglio M, et al.Symptoms of endocrine treatment and outcome in the BIG 1-98 study[J].Breast Cancer Res Treat, 2014, 143(1):159-169.
- 9. van de Velde CJ, Rea D, Seynaeve C, et al.Adjuvant tamoxifen and exemestane in early breast cancer (TEAM):a randomised phase 3 trial[J].Lancet, 2011, 377(9762):321-331.
- 10. Davies C, Pan H, Godwin J, et al.Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer:ATLAS, a randomised trial[J].Lancet, 2013, 381(9869):805-816.
- 11. Goss PE, Ingle JN, Martino S, et al.Impact of premenopausal status at breast cancer diagnosis in women entered on the placebocontrolled NCIC CTG MA17 trial of extended adjuvant letrozole[J].Ann Oncol, 2013, 24(2):355-361.
- 12. Berry DA, Cirrincione C, Henderson IC, et al.Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer[J].JAMA, 2006, 295(14):1658-1667.
- 13. International Breast Cancer Study Group (IBCSG).Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer:a randomized trial[J].J Natl Cancer Inst, 2002, 94(14):1054-1065.
- 14. Mehta RS, Barlow WE, Albain KS, et al.Combination anastrozole and fulvestrant in metastatic breast cancer[J].N Engl J Med, 2012, 367(5):435-444.
- 15. Bergh J, J?nsson PE, Lidbrink EK, et al.FACT:an open-label randomized phaseⅢstudy of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer[J].J Clin Oncol, 2012, 30(16):1919-1925.
- 16. Hugh J, Hanson J, Cheang MC, et al.Breast cancer subtypes and response to docetaxel in node-positive breast cancer:use of an immunohistochemical definition in the BCIRG 001 trial[J].J Clin Oncol, 2009, 27(8):1168-1176.
- 17. Roché H, Fumoleau P, Spielmann M, et al.Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients:the FNCLCC PACS 01 Trial[J].J Clin Oncol, 2006, 24(36):5664-5671.
- 18. Benz CC, Scott GK, Sarup JC, et al.Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu[J].Breast Cancer Res Treat, 1992, 24(2):85-95.
- 19. Ellis MJ, Coop A, Singh B, et al.Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer:evidence from a phaseⅢrandomized trial[J].J Clin Oncol, 2001, 19(18):3808-3816.
- 20. Kong X, Moran MS, Zhang N, et al.Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients[J].Eur J Cancer, 2011, 47(14):2084-2090.
- 21. 周波, 謝菲, 楊德啟.乳腺癌分子亞型預測新輔助化療療效的研究[J].中國腫瘤臨床, 2009, 36(4):199-202, 206.
- 22. Gianni L, Eiermann W, Semiglazov V, et al.Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial):a randomised controlled superiority trial with a parallel HER2-negative cohort[J].Lancet, 2010, 375(9712):377-384.
- 23. S?rlie T, Perou CM, Tibshirani R, et al.Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications[J].Proc Natl Acad Sci USA, 2001, 98(19):10869-10874.
- 24. Hayes DF, Thor AD, Dressler LG, et al.HER2 and response to paclitaxel in node-positive breast cancer[J].N Engl J Med, 2007, 357(15):1496-1506.
- 25. Press MF, Sauter G, Buyse M, et al.Alteration of topoisomeraseⅡ-alpha gene in human breast cancer:association with responsiveness to anthracycline-based chemotherapy[J].J Clin Oncol, 2011, 29(7):859-867.
- 26. Tan-Chiu E, Yothers G, Romond E, et al.Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer:NSABP B-31[J].J Clin Oncol, 2005, 23(31):7811-7819.
- 27. Slamon D, Eiermann W, Robert N, et al.Adjuvant trastuzumab in HER2-positive breast cancer[J].N Engl J Med, 2011, 365(14):1273-1283.
- 28. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al.Herceptin Adjuvant (HERA) Trial Study Team.Trastuzumab after adju vant chemotherapy in HER2-positive breast cancer[J].N Engl J Med, 2005, 353(16):1659-1672.
- 29. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al.2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA):an open-label, randomised controlled trial[J].Lancet, 2013, 382(9897):1021-1028.
- 30. Pivot X, Romieu G, Debled M, et al.6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE):a randomised phase 3 trial[J].Lancet Oncol, 2013, 14(8):741-748.
- 31. Slamon D, Eiermann W, Robert N, et al.PhaseⅢrandomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in her2neu positive early breast cancer patients:BCIRG 006 Study[J].Cancer Res, 2009, 69(24):Supplement 3.
- 32. Baselga J, Bradbury I, Eidtmann H, et al.Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO):a randomised, open-label, multicentre, phase 3 trial[J].Lancet, 2012, 379(9816):633-640.
- 33. Slamon DJ, Leyland-Jones B, Shak S, et al.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J].N Engl J Med, 2001, 344(11):783-792.
- 34. Marty M, Cognetti F, Maraninchi D, et al.Randomized phaseⅡtrial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:the M77001 study group[J].J Clin Oncol, 2005, 23(19):4265-4274.
- 35. Valero V, Forbes J, Pegram MD, et al.Multicenter phaseⅢrandomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study):two highly active therapeutic regimens[J].J Clin Oncol, 2011, 29(2):149-156.
- 36. Extra JM, Antoine EC, Vincent-Salomon A, et al.Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients:the observational Hermine study[J].Oncologist, 2010, 15(8):799-809.
- 37. Bachelot T, Romieu G, Campone M, et al.Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE):a singlegroup phase 2 study[J].Lancet Oncol, 2013, 14(1):64-71.
- 38. Dent R, Trudeau M, Pritchard KI, et al.Triple-negative breast cancer:clinical features and patterns of recurrence[J].Clin Cancer Res, 2007, 13(15 Pt 1):4429-4434.
- 39. De Laurentiis M, Cianniello D, Caputo R, et al.Treatment of triple negative breast cancer (TNBC):current options and future perspectives[J].Cancer Treat Rev, 2010, 36 Suppl 3:S80-S86.
- 40. de Ruijter TC, Veeck J, Tjan-Heijnen VC, et al.Characteristics of triple-negative breast cancer[J].J Cancer Res Clin Oncol, 2011, 137(2):183-192.
- 41. Nielsen TO, Hsu FD, Jensen K, et al.Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma[J].Clin Cancer Res, 2004, 10(16):5367-5374.
- 42. Abd El-Rehim DM, Ball G, Pinder SE, et al.High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses[J].Int J Cancer, 2005, 116(3):340-350.
- 43. Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al.Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer:final analysis of the randomized FinXX trial[J].J Clin Oncol, 2012, 30(1):11-18.
- 44. Wu J, Li S, Jia W, et al.Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triplenegative breast cancer[J].J Cancer Res Clin Oncol, 2011, 137(10):1505-1510.
- 45. Silver DP, Richardson AL, Eklund AC, et al.Efficacy of neoadjuvant cisplatin in triple-negative breast cancer[J].J Clin Oncol, 2010, 28(7):1145-1153.
- 46. Von Minckwitz G.A randomized phaseⅡtrial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto-GBG 66)[J].J Clin Oncol, 2013, suppl, abstr 1004.
- 47. Sikov WM, Berry DA, Perou CM, et al.Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC):CALGB 40603(Alliance)[C].The 2013 San Antonio Breast Cancer Symposium, December 10-14, 2013, Abstract S5-0.
- 48. Baselga J, Gomez P, Awada A, et al.The addition of cetuximab to cisplatin increases overall response rate (ORR) and progressionfree survival (PFS) in metastatic triple-negative breast cancer (TNBC):results of a randomized phaseⅡstudy (BALI-1)[J].Ann Oncol, 2010, 21(Suppl 8):2740.
- 49. Cameron D, Brown J, Dent R, et al.Adjuvant bevacizumabcontaining therapy in triple-negative breast cancer (BEATRICE):primary results of a randomised, phase 3 trial[J].Lancet Oncol, 2013, 14(10):933-942.
- 50. O'Shaughnessy J, Osborne C, Pippen JE, et al.Iniparib plus chemotherapy in metastatic triple-negative breast cancer[J].N Engl J Med, 2011, 364(3):205-214.
- 51. Gelmon KA, Tischkowitz M, Mackay H, et al.Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer:a phase 2, multicentre, open-label, non-randomised study[J].Lancet Oncol, 2011, 12(9):852-861.
- 52. Finetti P, Cervera N, Charafe-Jauffret E, et al.Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis[J].Cancer Res, 2008, 68(3):767-776.
- 53. Lavasani MA, Moinfar F.Molecular classification of breast carcinomas with particular emphasis on "basal-like" carcinoma:a critical review[J].Biophotonics, 2012, 5(4):345-366.